Abstract: A method for maintaining packet's source network identification information while aggregating packets from a plurality of networks is provided. An ingress packet is processed to extract a plurality of packet header fields and port identifier. A first hash index is generated by hashing information associated with the plurality of packet header fields. The extracted port identifier is stored in a hash table using the generated first hash index. The ingress packet is forwarded to one or more inline tool devices. An egress packet received from the one or more inline tools is processed to extract the plurality of packet header fields. A second hash index is generated by hashing information associated with the plurality of packet header fields. The port identifier is retrieved from the hash table based on the generated second hash index. The egress packet is transmitted to a switching device based on the retrieved port identifier.

Abstract: A method for determining a routing for packets aggregated from multiple Layer 2 (L2) networks is provided. An ingress packet is received from an ingress inline network port and is processed to extract a source Media Access Control (MAC) address and a port identifier associated with the source MAC address. The extracted source MAC address of the ingress packet is looked up in a MAC address table. The ingress packet is forwarded to an inline tool device. When an egress packet is received back from the inline tool device it is processed to extract source and destination MAC addresses. The extracted source and destination MAC addresses of the egress packet are looked up in the MAC address table. The egress packet is transmitted to an egress inline port based on the looked up destination MAC address.

Abstract: A method for determining a routing for packets aggregated from multiple Layer 2 (L2) networks is provided. An ingress packet is received from an ingress inline network port and is processed to extract a source Media Access Control (MAC) address and a port identifier associated with the source MAC address. The extracted source MAC address of the ingress packet is looked up in a MAC address table. The ingress packet is forwarded to an inline tool device. When an egress packet is received back from the inline tool device it is processed to extract source and destination MAC addresses. The extracted source and destination MAC addresses of the egress packet are looked up in the MAC address table. The egress packet is transmitted to an egress inline port based on the looked up destination MAC address.

Abstract: A method for maintaining packet's source network identification information while aggregating packets from a plurality of networks is provided. An ingress packet is processed to extract a plurality of packet header fields and port identifier. A first hash index is generated by hashing information associated with the plurality of packet header fields. The extracted port identifier is stored in a hash table using the generated first hash index. The ingress packet is forwarded to one or more inline tool devices. An egress packet received from the one or more inline tools is processed to extract the plurality of packet header fields. A second hash index is generated by hashing information associated with the plurality of packet header fields. The port identifier is retrieved from the hash table based on the generated second hash index. The egress packet is transmitted to a switching device based on the retrieved port identifier.

Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3/R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase medicated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.

Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.

Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.

Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

Abstract: This invention is directed generally to a process for making substituted pyrazoles, tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers. The substituted pyrazoles correspond in structure to Formula (I): wherein R3A, R3B, R3C, Y1, Y2, Y3, Y4, and Y5 are as defined in the specification.

Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R1, R2, R3 and R4 are as described in the specification.

Abstract: Disclosed are compounds of Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

Abstract: This invention is directed generally to a process for making substituted pyrazoles, tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers. The substituted pyrazoles correspond in structure to Formula (I): wherein R3A, R3B, R3C, Y1, Y2, Y3, Y4, and Y5 are as defined in the specification.

Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders.

Abstract: This invention is directed generally to pyrazoles that, inter alia, inhibit p38 kinase, TNF, and/or cyclooxygenase-2 activity.

Abstract: Disclosed are compounds Formula I 1

Abstract: This invention is directed generally to a process for making substituted pyrazoles, tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers.

Abstract: This invention is directed generally to a process for making substituted pyrazoles, tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers.